• Policy
• Onivyde listed at ₩672,320 as RSA refund type
• by Kim, Jung-Ju Jul 26, 2021 05:50am

• Policy
• New PBAC members to make big reimbursmeent decisions in 2H
• by Lee, Hye-Kyung Jul 26, 2021 05:50am

• Opinion
• [Reporter's view] The MFDS shouldn't selectively explain
• by Lee, Tak-Sun Jul 26, 2021 05:50am

• Company
• Mother's and Kyung Dong won the patent dispute
• by Kim, Jin-Gu Jul 26, 2021 05:50am

• Policy
• Controversy over the manufacturing location of QTP104
• by Lee, Tak-Sun Jul 26, 2021 05:50am

• Company
• Glaucoma tx Taflotan demonstrates long-term effectiveness
• by Jul 26, 2021 05:49am

• Policy
• Tamsulosin and Donepezil insurance cuts were most objected
• by Lee, Hye-Kyung Jul 23, 2021 05:57am

• Policy
• Moderna vaccine shows 94% prevention in overseas trial
• by Kim, Jung-Ju Jul 23, 2021 05:57am

• Company
• Generics for Betmiga, ↑19% market share in just one year
• by Kim, Jin-Gu Jul 23, 2021 05:57am

• Company
• Sales of Lyrica's generics sales beat Lyrica in nine years
• by Kim, Jin-Gu Jul 23, 2021 05:57am